Vu H. Duong - Concepedia

Author

Vu H. Duong

Also Known As

Duong Vu, Duong, Vu, V. Duong, V. H. Duong, Vu Duong, Vu Duong (9221414), Vu H Duong, Vu H. Duong, Vu Hong Duong, Vu Huy Hoang Duong

187

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

University of Maryland, Baltimore U-M Rogel Cancer Center Moffitt Cancer Center Emory University Oregon Health & Science University

About

Vu H. Duong is an author at University of Maryland, Baltimore specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	21	1.1K
2	Health Sciences	9	9	371
3	Cell Biology	2	2	235
4	Public Health	1	1	18
5	Biostatistics	1	1	181

Vu H. Duong

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
TGF-β-RI Kinase Inhibitor SD-208 Reduces the Development and Progression of Melanoma Bone Metastases Khalid S. Mohammad, Delphine Javelaud, Pierrick G.J. Fournier, Cancer Research Melanoma Cell LinesTumor BiologyBone Morphogenic ProteinMelanoma Bone MetastasesMedicine	2010	217
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer Nidal Muvarak, Khadiza Chowdhury, Limin Xia, Cancer Cell Cytotoxic EffectsA Potential TherapyMedicineParp InhibitorsAnti-cancer Agent	2016	207
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial Amy Burd, Ross L. Levine, Amy S. Ruppert, Nature Medicine Hematological MalignancyProspective Genomic ProfilingOncologyMedicineAcute Myeloid Leukemia	2020	181
Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy Bhavana Bhatnagar, Vu H. Duong, Theodore Stewart Gourdin, Leukemia & lymphoma/Leukemia and lymphoma Mixed-phenotype Acute LeukemiaPharmacotherapyMyeloid NeoplasiaHematological MalignancyAcute Myeloid Leukemia	2013	56
Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia Ashkan Emadi, Jennie Y. Law, Erin T. Strovel, Cancer Chemotherapy and Pharmacology Plasma GlutamineMedicineAdult PatientsHematologyAsparaginase Erwinia Chrysanthemi	2017	53
Poor Outcome of Patients With Myelodysplastic Syndrome After Azacitidine Treatment Failure Vu H. Duong, Karen Lin, Tea Reljic, Clinical Lymphoma Myeloma & Leukemia Hematological MalignancyAzacitidine Treatment FailureMyelodysplastic SyndromePoor OutcomeHematology	2013	51
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation Keith W. Pratz, Michelle A. Rudek, B. Douglas Smith, Biology of Blood and Marrow Transplantation	2019	42
Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management Najeebah A. Bade, Crystal Lu, Ciera Patzke, Journal of Oncology Pharmacy Practice Translational MedicineOncologyPegylated AsparaginaseInstitutional GuidelinePharmacology	2019	38
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure Michael Jaglal, Vu H. Duong, Celeste Bello, Leukemia Research Hematological MalignancyMyelodysplastic SyndromeMedicineAcute Myeloid LeukemiaAzanucleoside Failure	2013	36
A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias Jeffrey E. Lancet, Vu H. Duong, Elliott F. Winton, Clinical Cancer Research	2011	34

Page 1